HCV / Hepatitis

A 4-week course of glecaprevir/pibrentasvir achieved sustained virologic response in 84% of patients with early hepatitis C infection in the PURGE-C trial, suggesting potential for shorter, more accessible treatment regimens pending further validation.

This week, learn about the Center for Discovery and Innovation's research around antivirals, the hepatitis C bill in Congress, how AI is influencing antimicrobial development, and more.

Through the bipartisan Cure Hepatitis C Act of 2025, legislation seeks to provide nationwide hepatitis C treatment and strengthen public health infrastructure by expanding testing, treatment, and prevention through a subscription-based model.

Your liver silently powers and protects your body every day, but untreated hepatitis infections, excessive alcohol, and poor diet can destroy its vital cells, leading to fatigue, cirrhosis, and liver cancer if not prevented through awareness and care.

A June–September roundup spanning hepatitis research and surveillance data, FDA and ACIP policy moves, diet and diagnostics insights, and pipeline updates from screening innovations to HBV/HDV/HCV trials and approvals.

This week, review of ACIP’s latest decisions, analysis links food insecurity with higher long COVID risk, and advocacy for immune-informed antibiotic development with updated susceptibility testing.

Georges C.Benjamin, MD, executive director of the American Public Health Association, details practical implications for clinical teams.

Infectious disease pediatrician Sharon Nachman, MD, offers insights on what is already being done in clinical practice with regards to vaccines, the CDC committee's votes on the MMRV and hepatitis b vaccines, and understanding how they will affect these immunizations going forward.

The non-vote leaves the current immunization recommendation in place, but led to further debate amongst the CDC's ACIP panelists on the hepatitis B vaccine as well as questioning the current process of the delivery of data and whether they would be utilizing working groups and grading studies.

The committee voted to change the MMRV vaccine recommendation, left panelists uncertain around a second MMRV immunization vote, and delayed the hepatitis B vaccine vote until Friday.

Vincent Lo Re, MD, MSCE, FISPE, reviews HR-pQCT findings, IL-18 and TNF-α declines, and guidance for clinicians.

At the ICE-HBV Cure Symposium, EBT-107 showed reduced intrahepatic HBV DNA and no increase in chromosomal translocations, supporting a path toward first-in-human testing.

Bluejay Therapeutics’ investigational therapy, brelovitug, offers weekly self-administered injections and will be studied against the only approved treatment outside the US.

This week, people with HIV are living longer on antiretroviral therapy but face elevated comorbidity risks, requiring tailored screening and multidisciplinary care as they age, and more.

A decade-long study finds the ratio independently predicts risk, with patients aged ≥30 facing higher progression rates.

Philippa Easterbrook, MD, MPH, FRCP, explains barriers in primary care, the promise of community models, and how simplified guidelines could expand access to treatment.

Ty Stoner of Walgreens Specialty Pharmacy on navigating barriers, building partnerships, and improving access for vulnerable populations.

Vir initiates phase 2b head-to-head trial of novel combination therapy vs bulevirtide.

This week, from synthetic biosecurity concerns to gaps in maternal hepatitis C screening, rising COVID cases, antimicrobial resistance, fast-tracked CF therapies, and more.

Despite updated guidelines for universal hepatitis C virus screening in pregnancy, testing rates remain well below targets, missing chances to prevent perinatal transmission.

Study reveals notable sex-based disparities in liver complication risk among adults with cirrhosis, particularly in nonviral cases.

The study will examine the switch to the combination of tobevibart and elebsiran in patients not achieving undetectable hepatitis D virus RNA despite bulevirtide treatment.

Unsaturated fats in vegetable oils help reduce inflammation and modulate organ metabolism, leading to decreased ALT, AST, and TBIL levels.

Global modeling identifies vertical transmission burden and underscores need for maternal screening policies.

First representative data highlight regional and demographic variations, underscoring the need for enhanced vaccination and targeted interventions.